Wells Fargo Maintains Equal-Weight on NovoCure, Raises Price Target to $17

Benzinga Newsdesk www.benzinga.com Positive 67.7%

Neg 0% Neu 0% Pos 67.7%

Wells Fargo analyst Larry Biegelsen maintains NovoCure (NASDAQ:NVCR) with a Equal-Weight and raises the price target from $13.5 to $17.